Locoregional Stomach Cancer

Metastatic Gastric Cancer

Male, 52 years

Patient Internal ID: 262442637

ICD-10 code

C16.3 Malignant Neoplasm of Pyloric Antrum

Diagnosis (Incl. Metastases/Stage) and Year

July 2018
1. Gastroesophageal Junction moderately differentiated (G2) Tubular Carcinoma of the Stomach ypT2N0 LVI-0, CK7(+)/CK20(-)/HER2 (0+). 2. Gastric poorly differentiated (G3) EBV-associated Carcinoma of the Stomach pT4aN0 LVI-2, CK7(-)/CK20(-)/HEPA(-),HER2 (0+). Disease progression in June 2019, Metastasis in Lymph Nodes. Disease progression in March 2020, Metastasis in Adrenal Gland. Disease progression in September 2020, Paraaortic Metastasis.

Previous Treatment

Surgery (Gastrectomy), Chemotherapy (Cisplatin + %-FU), Chemotherapy (Paclitaxel) + Biologic Therapy (Ramucirumab).

Prognosis and Survival Expectation

The prognosis for Metastatic Gastric Cancer remains poor, with a median survival of ~14 months since disease progression. The 5-year survival for patients with Metastatic Gastric Cancer is 5.2%.

Treatment Provided

Allogeneic Umbilical Cord Bood Derived NK Cells (4 doses) together with Interleukin-2, over a period of 1 month.

Patient Survival/Condition and Year
Date of Review: 02/12/2023

The patient has survived for 44 months since the diagnosis and 24 months since disease progression. It can be concluded that the addition of Immunotherapy, alongside Surgery, Chemotherapy and Biological Therapy, has extended patient survival by an estimate of around 10 months.